Abstract
BACKGROUND. Protocol endoscopy with biopsy is currently the gold standard of small bowel transplantion (SBTx) monitoring, however it is invasive, costly, needs skilled operator, may require anesthesia and may cause complications. We investigated fecal calprotectin level (FCL) as a candidate noninvasive marker for monitoring patients after SBTx. METHODS. A pilot study was performed to test the use of FCL measurement in following up SBTx patients. Ileostomy effluents were collected at various postoperative days before endoscopy and biopsy. FCLs were measured by enzyme-linked immunosorbent assay and a cut-off level of 100 ng/mg was considered positive. The results were retrospectively evaluated in combination with clinical, endoscopic, and histopathological findings. FCLs are presented as median nanogram per milligram. RESULTS. FCLs were measured in 122 samples that were obtained from 29 patients after SBTx. Only 1 of 69 positive FCL did not accompany abnormal findings. Retrospective evaluation showed that 11 samples from six patients (FCL: 217) coincided with rejection episodes, six samples from three patients (FCL: 125) coincided with viral enteritis, 51 samples from 21 patients (FCL: 207) coincided with nonspecific inflammation, 11 samples from two patients (FCL: 998) coincided with chronic intestinal ulceration, and finally 50 samples from 19 patients (FCL: 43) coincided with normal findings. No significant FCL difference was found between rejection, infection, and inflammation. FCL evolution in individuals showed that FCL can predict rejection days before histopathological diagnosis. CONCLUSION. FCL is a sensitive test for ongoing organic intestinal allograft pathologies. It might be useful as prescreening marker to avoid unnecessary endoscopies.
| Original language | English |
|---|---|
| Pages (from-to) | 1281-1286 |
| Number of pages | 6 |
| Journal | Transplantation |
| Volume | 85 |
| Issue number | 9 |
| DOIs | |
| State | Published - May 1 2008 |
Fingerprint
Keywords
- Allograft monitoring
- Calprotectin
- Small bowel transplantation
ASJC Scopus subject areas
- Transplantation
- Immunology
Cite this
Fecal calprotectin level measurements in small bowel allograft monitoring : A pilot study. / Akpinar, Edip; Vargas, Jacinto; Kato, Tomaoki; Smith, Lesley J; Hernandez, Erick; Selvaggi, Gennaro; Nishida, Seigo; Moon, Jang; Island, Eddie; Levi, David; Ruiz, Phillip; Tzakis, Andreas G.
In: Transplantation, Vol. 85, No. 9, 01.05.2008, p. 1281-1286.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fecal calprotectin level measurements in small bowel allograft monitoring
T2 - A pilot study
AU - Akpinar, Edip
AU - Vargas, Jacinto
AU - Kato, Tomaoki
AU - Smith, Lesley J
AU - Hernandez, Erick
AU - Selvaggi, Gennaro
AU - Nishida, Seigo
AU - Moon, Jang
AU - Island, Eddie
AU - Levi, David
AU - Ruiz, Phillip
AU - Tzakis, Andreas G.
PY - 2008/5/1
Y1 - 2008/5/1
N2 - BACKGROUND. Protocol endoscopy with biopsy is currently the gold standard of small bowel transplantion (SBTx) monitoring, however it is invasive, costly, needs skilled operator, may require anesthesia and may cause complications. We investigated fecal calprotectin level (FCL) as a candidate noninvasive marker for monitoring patients after SBTx. METHODS. A pilot study was performed to test the use of FCL measurement in following up SBTx patients. Ileostomy effluents were collected at various postoperative days before endoscopy and biopsy. FCLs were measured by enzyme-linked immunosorbent assay and a cut-off level of 100 ng/mg was considered positive. The results were retrospectively evaluated in combination with clinical, endoscopic, and histopathological findings. FCLs are presented as median nanogram per milligram. RESULTS. FCLs were measured in 122 samples that were obtained from 29 patients after SBTx. Only 1 of 69 positive FCL did not accompany abnormal findings. Retrospective evaluation showed that 11 samples from six patients (FCL: 217) coincided with rejection episodes, six samples from three patients (FCL: 125) coincided with viral enteritis, 51 samples from 21 patients (FCL: 207) coincided with nonspecific inflammation, 11 samples from two patients (FCL: 998) coincided with chronic intestinal ulceration, and finally 50 samples from 19 patients (FCL: 43) coincided with normal findings. No significant FCL difference was found between rejection, infection, and inflammation. FCL evolution in individuals showed that FCL can predict rejection days before histopathological diagnosis. CONCLUSION. FCL is a sensitive test for ongoing organic intestinal allograft pathologies. It might be useful as prescreening marker to avoid unnecessary endoscopies.
AB - BACKGROUND. Protocol endoscopy with biopsy is currently the gold standard of small bowel transplantion (SBTx) monitoring, however it is invasive, costly, needs skilled operator, may require anesthesia and may cause complications. We investigated fecal calprotectin level (FCL) as a candidate noninvasive marker for monitoring patients after SBTx. METHODS. A pilot study was performed to test the use of FCL measurement in following up SBTx patients. Ileostomy effluents were collected at various postoperative days before endoscopy and biopsy. FCLs were measured by enzyme-linked immunosorbent assay and a cut-off level of 100 ng/mg was considered positive. The results were retrospectively evaluated in combination with clinical, endoscopic, and histopathological findings. FCLs are presented as median nanogram per milligram. RESULTS. FCLs were measured in 122 samples that were obtained from 29 patients after SBTx. Only 1 of 69 positive FCL did not accompany abnormal findings. Retrospective evaluation showed that 11 samples from six patients (FCL: 217) coincided with rejection episodes, six samples from three patients (FCL: 125) coincided with viral enteritis, 51 samples from 21 patients (FCL: 207) coincided with nonspecific inflammation, 11 samples from two patients (FCL: 998) coincided with chronic intestinal ulceration, and finally 50 samples from 19 patients (FCL: 43) coincided with normal findings. No significant FCL difference was found between rejection, infection, and inflammation. FCL evolution in individuals showed that FCL can predict rejection days before histopathological diagnosis. CONCLUSION. FCL is a sensitive test for ongoing organic intestinal allograft pathologies. It might be useful as prescreening marker to avoid unnecessary endoscopies.
KW - Allograft monitoring
KW - Calprotectin
KW - Small bowel transplantation
UR - http://www.scopus.com/inward/record.url?scp=43449136778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43449136778&partnerID=8YFLogxK
U2 - 10.1097/TP.0b013e31816dcea2
DO - 10.1097/TP.0b013e31816dcea2
M3 - Article
VL - 85
SP - 1281
EP - 1286
JO - Transplantation
JF - Transplantation
SN - 0041-1337
IS - 9
ER -